The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
 
Paul K. Paik
Honoraria - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda
Research Funding - Celgene; EMD Serono
Travel, Accommodations, Expenses - EMD Serono
 
Linda Su Hyun Ahn
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Pang-Dian Fan
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; Ascentage Pharma; AstraZeneca; Bicycle Therapeutics; Bridge Medicines; Celgene; Daiichi Sankyo; Genentech/Roche; Harpoon Therapeutics; Ipsen; Loxo; PharmaMar; PharmaMar
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)